|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
JP3811775B2
(ja)
|
2000-07-19 |
2006-08-23 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
|
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002022605A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
AU2002216650A1
(en)
|
2000-10-31 |
2002-05-15 |
Lynn Bonham |
Triazine derivatives as lpaat-b inhibitors and uses thereof
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6670357B2
(en)
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
CN1486302A
(zh)
*
|
2000-12-07 |
2004-03-31 |
CV���ƹ�˾ |
作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
|
|
BR0116452A
(pt)
|
2000-12-21 |
2003-09-30 |
Glaxo Group Ltd |
Composto, composição farmacêutica, uso de um composto
|
|
US6989385B2
(en)
|
2000-12-21 |
2006-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
CA2671776C
(en)
*
|
2001-01-31 |
2012-12-18 |
H. Lundbeck A/S |
Gal3 receptor antagonists for the treatment of depression
|
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
US6887873B2
(en)
|
2001-03-23 |
2005-05-03 |
Aventis Pharma S.A. |
Triazine derivatives and their application as antitelomerase agents
|
|
KR100798579B1
(ko)
*
|
2001-03-31 |
2008-01-28 |
동화약품공업주식회사 |
신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
|
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
|
CA2450934A1
(en)
*
|
2001-06-19 |
2002-12-27 |
Marco Dodier |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
|
AU2002316421B2
(en)
|
2001-06-26 |
2008-05-15 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-ALPHA expression
|
|
DE60235470D1
(de)
*
|
2001-06-26 |
2010-04-08 |
Pharmacopeia Inc |
N-heterocyclische inhibitoren der expression von tnf-alpha
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7132423B2
(en)
|
2001-09-21 |
2006-11-07 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7169785B2
(en)
|
2001-09-21 |
2007-01-30 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7163943B2
(en)
|
2001-09-21 |
2007-01-16 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
WO2003024926A2
(en)
*
|
2001-09-21 |
2003-03-27 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7173032B2
(en)
|
2001-09-21 |
2007-02-06 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7112587B2
(en)
|
2001-09-21 |
2006-09-26 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
AU2002342018A1
(en)
*
|
2001-10-12 |
2003-04-28 |
New York University |
Trisubstituted triazines compounds with antitubulin activity
|
|
HUP0402106A3
(en)
|
2001-11-01 |
2009-07-28 |
Janssen Pharmaceutica Nv |
Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
|
|
WO2003047516A2
(en)
*
|
2001-11-30 |
2003-06-12 |
Synta Pharmaceuticals Corporation |
Pyrimidine compounds
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
KR100516434B1
(ko)
*
|
2002-04-04 |
2005-09-22 |
(주) 비엔씨바이오팜 |
6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
|
|
US20040014744A1
(en)
*
|
2002-04-05 |
2004-01-22 |
Fortuna Haviv |
Substituted pyridines having antiangiogenic activity
|
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
US20040082627A1
(en)
*
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
EP2316459B1
(en)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
KR101297924B1
(ko)
*
|
2002-07-29 |
2013-08-20 |
리겔 파마슈티칼스, 인크. |
2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
|
|
RU2491071C2
(ru)
*
|
2002-07-29 |
2013-08-27 |
Райджел Фармасьютикалз, Инк. |
Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина
|
|
AU2003265349A1
(en)
*
|
2002-08-02 |
2004-02-23 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
AU2003272740A1
(en)
*
|
2002-10-01 |
2004-04-23 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
|
|
US20050102708A1
(en)
*
|
2003-03-12 |
2005-05-12 |
Laurent Lecanu |
Animal model simulating neurologic disease
|
|
US7223766B2
(en)
|
2003-03-28 |
2007-05-29 |
Scios, Inc. |
Bi-cyclic pyrimidine inhibitors of TGFβ
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
|
NZ546011A
(en)
|
2003-10-21 |
2009-09-25 |
Warner Lambert Co |
Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
|
AU2004295050A1
(en)
|
2003-11-24 |
2005-06-16 |
F.Hoffmann-La Roche Ag |
Pyrazolyl and imidazolyl pyrimidines
|
|
MXPA06005879A
(es)
*
|
2003-11-24 |
2007-01-26 |
Prometic Biosciences Inc |
Dimeros de triazina para el tratamiento de enfermedades autoinmunes.
|
|
WO2005054239A1
(en)
*
|
2003-12-05 |
2005-06-16 |
Bayer Healthcare Ag |
2-aminopyrimidine derivatives
|
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2005212438A1
(en)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
US7335770B2
(en)
|
2004-03-24 |
2008-02-26 |
Reddy U5 Therapeutics, Inc. |
Triazine compounds and their analogs, compositions, and methods
|
|
ES2364340T3
(es)
*
|
2004-03-30 |
2011-08-31 |
Vertex Pharmaceuticals Incorporated |
Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
JP4560329B2
(ja)
*
|
2004-05-07 |
2010-10-13 |
全薬工業株式会社 |
５−アミノピリミジン化合物
|
|
EP1763526B1
(en)
|
2004-06-28 |
2009-06-24 |
Bayer Schering Pharma AG |
4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
AU2005284904A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
MX2007003318A
(es)
|
2004-09-20 |
2007-05-18 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como agentes terapeuticos.
|
|
BRPI0515500A
(pt)
|
2004-09-20 |
2008-07-29 |
Xenon Pharmaceuticals Inc |
derivados piridazina para inibição de estearoil-coa-desaturase
|
|
AU2005286647A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
AU2005286728A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
CN101084211A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
杂环衍生物及其作为治疗剂的用途
|
|
BRPI0515482A
(pt)
|
2004-09-20 |
2008-07-22 |
Xenon Pharmaceuticals Inc |
derivados heterocìclicos e seus usos como agentes terapêuticos
|
|
MX2007003332A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
|
|
KR20070058602A
(ko)
|
2004-09-30 |
2007-06-08 |
티보텍 파마슈티칼즈 리미티드 |
Ｈｃｖ 저해 바이-사이클릭 피리미딘
|
|
EP1799699A1
(en)
|
2004-10-13 |
2007-06-27 |
Wyeth |
Analogs of 17-hydroxywortmannin as pi3k inhibitors
|
|
PT1807077T
(pt)
*
|
2004-10-22 |
2017-01-06 |
Janssen Pharmaceutica Nv |
Inibidores de quinase c-fms
|
|
NZ555289A
(en)
|
2004-10-22 |
2010-10-29 |
Janssen Pharmaceutica Nv |
Inhibitors of c-fms kinase
|
|
US7645755B2
(en)
|
2004-10-22 |
2010-01-12 |
Janssen Pharmaceutical N.V. |
Inhibitors of c-fms kinase
|
|
SI1814878T1
(sl)
|
2004-11-24 |
2012-06-29 |
Rigel Pharmaceuticals Inc |
Spojine spiro-2,4-pirimidindiamina in njihova uporaba
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
BRPI0606793A8
(pt)
|
2005-02-04 |
2018-03-13 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
|
|
SI1853588T1
(sl)
|
2005-02-16 |
2008-10-31 |
Astrazeneca Ab |
Kemične spojine
|
|
WO2006105222A2
(en)
*
|
2005-03-25 |
2006-10-05 |
Scios Inc. |
Carboxamide inhibitors of tgfb
|
|
US8030318B2
(en)
|
2005-03-25 |
2011-10-04 |
Tibotec Pharmaceuticals Ltd. |
Fused bicyclic inhibitors of HCV
|
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
|
US20080287437A1
(en)
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
|
CA2618646A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
|
NZ564222A
(en)
*
|
2005-06-14 |
2011-10-28 |
Taigen Biotechnology Co Ltd |
Pyrimidine compounds
|
|
US7592451B2
(en)
|
2005-06-23 |
2009-09-22 |
New York University |
Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
|
|
CA2622372A1
(en)
*
|
2005-09-13 |
2007-03-22 |
Palau Pharma, S.A. |
2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
|
|
AR056556A1
(es)
|
2005-09-30 |
2007-10-10 |
Astrazeneca Ab |
Imidazo(1,2-a)piridina con actividad antiproliferacion celular
|
|
JP2009513615A
(ja)
|
2005-10-28 |
2009-04-02 |
アストラゼネカ アクチボラグ |
癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
|
|
MX2008005814A
(es)
|
2005-11-03 |
2008-10-15 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasa.
|
|
US20070179125A1
(en)
*
|
2005-11-16 |
2007-08-02 |
Damien Fraysse |
Aminopyrimidines useful as kinase inhibitors
|
|
JP5555426B2
(ja)
*
|
2005-12-01 |
2014-07-23 |
ビーエーエスエフ ソシエタス・ヨーロピア |
スルホンアミド類の製造方法
|
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
UA95940C2
(uk)
|
2006-01-17 |
2011-09-26 |
Вертекс Фармасьютикалс Інкорпорейтед |
Азаіндоли як інгібітори кіназ януса
|
|
WO2007124319A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
US8674100B2
(en)
|
2006-04-20 |
2014-03-18 |
Janssen Pharmaceutica, N.V. |
Inhibitors of C-FMS kinase
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
PL2021335T3
(pl)
|
2006-04-20 |
2011-10-31 |
Janssen Pharmaceutica Nv |
Związki heterocykliczne jako inhibitory kinazy C-FMS
|
|
PL2044056T3
(pl)
*
|
2006-07-14 |
2013-01-31 |
Novartis Ag |
Pochodne pirymidyny jako inhibitory ALK-5
|
|
EP2441757A1
(en)
|
2006-07-31 |
2012-04-18 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
|
EP2059512A1
(en)
*
|
2006-08-01 |
2009-05-20 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
|
CA2665438C
(en)
|
2006-10-04 |
2014-12-02 |
Tibotec Pharmaceuticals Ltd. |
Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
|
|
US8093246B2
(en)
|
2006-12-14 |
2012-01-10 |
Lexicon Pharmaceuticals, Inc. |
O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
|
|
CL2008000467A1
(es)
*
|
2007-02-14 |
2008-08-22 |
Janssen Pharmaceutica Nv |
Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
US8022209B2
(en)
|
2007-09-12 |
2011-09-20 |
Janssen Pharmaceutica Nv |
Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
|
|
EP2573087A1
(en)
|
2007-09-21 |
2013-03-27 |
Array Biopharma, Inc. |
Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
CN101821233B
(zh)
|
2007-10-12 |
2016-06-29 |
巴斯夫欧洲公司 |
生产磺酸二酰胺的方法
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
AU2008340421B2
(en)
*
|
2007-12-21 |
2013-12-19 |
F. Hoffmann-La Roche Ag |
Heteroaryl derivatives as orexin receptor antagonists
|
|
WO2009087127A1
(en)
|
2008-01-11 |
2009-07-16 |
F. Hoffmann-La Roche Ag |
Modulators for amyloid beta
|
|
JP5328816B2
(ja)
|
2008-02-22 |
2013-10-30 |
エフ．ホフマン−ラ ロシュ アーゲー |
アミロイドβの調節薬
|
|
DK2268635T3
(en)
*
|
2008-04-21 |
2015-09-14 |
Taigen Biotechnology Co Ltd |
Heterocyclic Compounds
|
|
MX2010013726A
(es)
|
2008-06-12 |
2011-01-14 |
Janssen Pharmaceutica Nv |
Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
ATE547402T1
(de)
|
2008-09-02 |
2012-03-15 |
Boehringer Ingelheim Int |
7-(piperazin-1-ylmethyl)-1h-indol-2-carbonsäure (phenyl) -amidderivate und verwandte verbindungen als p38 map-kinase-inhibitoren zur behandlung von atemwegserkrankungen
|
|
AU2009289378A1
(en)
|
2008-09-02 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Novel benzamides, production thereof, and use thereof as medicaments
|
|
WO2010040661A1
(en)
|
2008-10-09 |
2010-04-15 |
F. Hoffmann-La Roche Ag |
Modulators for amyloid beta
|
|
AU2009312856A1
(en)
|
2008-11-10 |
2010-05-14 |
F. Hoffmann-La Roche Ag |
Heterocyclic gamma secretase modulators
|
|
US9023834B2
(en)
|
2008-11-13 |
2015-05-05 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
|
WO2010114900A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-piperidine compounds
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
BRPI1010887A2
(pt)
*
|
2009-06-08 |
2016-12-27 |
California Capital Equity Llc |
derivados de triazina e suas aplicações terapêuticas.
|
|
EP2440053A4
(en)
*
|
2009-06-09 |
2012-10-31 |
California Capital Equity Llc |
BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
|
|
LT3141252T
(lt)
|
2009-06-17 |
2018-11-12 |
Vertex Pharmaceuticals Inc. |
Gripo virusų replikacijos inhibitoriai
|
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
KR20130065632A
(ko)
*
|
2010-04-28 |
2013-06-19 |
다이이찌 산쿄 가부시키가이샤 |
［５，６］복소 고리 화합물
|
|
TWI513694B
(zh)
*
|
2010-05-11 |
2015-12-21 |
Amgen Inc |
抑制間變性淋巴瘤激酶的嘧啶化合物
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
AU2011336764B2
(en)
*
|
2010-11-29 |
2017-02-23 |
Galleon Pharmaceuticals, Inc. |
Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
|
|
US20120295911A1
(en)
|
2010-11-29 |
2012-11-22 |
Galleon Pharmaceuticals, Inc. |
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
|
|
RU2013132681A
(ru)
|
2010-12-16 |
2015-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы репликации вирусов гриппа
|
|
TWI572599B
(zh)
*
|
2011-03-28 |
2017-03-01 |
Ｍｅｉ製藥公司 |
（α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
|
FR2983859B1
(fr)
*
|
2011-12-12 |
2014-01-17 |
Sanofi Sa |
Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
|
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
BR112014022790B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
|
|
CA2866852C
(en)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
IN2014DN08481A
(https=)
*
|
2012-03-16 |
2015-05-08 |
Impossible Foods Inc |
|
|
ES2658773T3
(es)
|
2012-08-07 |
2018-03-12 |
Janssen Pharmaceutica N.V. |
Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
|
|
CN104870454B
(zh)
|
2012-08-07 |
2020-03-03 |
詹森药业有限公司 |
用于制备杂环酯衍生物的方法
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2014116772A2
(en)
*
|
2013-01-25 |
2014-07-31 |
Bristol-Myers Squibb Company |
Squaric derivatives for the treatment of hepatitis c
|
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
|
US9656992B2
(en)
*
|
2013-03-07 |
2017-05-23 |
Bristol-Myers Squibb Company |
Pyrimidine compounds for the treatment of hepatitis C
|
|
CN105593215B
(zh)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
|
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015010297A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
CN104903312B
(zh)
*
|
2013-10-07 |
2019-01-29 |
卡德门企业有限公司 |
Rho激酶抑制剂
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
GB201403093D0
(en)
|
2014-02-21 |
2014-04-09 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
NZ723859A
(en)
|
2014-03-14 |
2023-01-27 |
Servier Lab |
Pharmaceutical compositions of therapeutically active compounds and their uses
|
|
CR20170077A
(es)
|
2014-08-04 |
2017-06-26 |
Nuevolution As |
Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
EP3294717B1
(en)
|
2015-05-13 |
2020-07-29 |
Vertex Pharmaceuticals Inc. |
Methods of preparing inhibitors of influenza viruses replication
|
|
EP3294735B8
(en)
|
2015-05-13 |
2022-01-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
|
KR102699521B1
(ko)
|
2015-10-15 |
2024-08-26 |
르 라보레또레 쎄르비에르 |
악성 종양의 치료를 위한 조합물 요법
|
|
FI3362065T3
(fi)
|
2015-10-15 |
2024-06-19 |
Servier Lab |
Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
|
|
CN105384702B
(zh)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
三取代均三嗪类化合物及其制备方法
|
|
CN105399695B
(zh)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
三嗪类化合物及其制备方法和用途
|
|
MX383072B
(es)
|
2015-12-24 |
2025-03-13 |
Univ California |
Reguladores del cftr y métodos para su uso
|
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
|
JP2020531511A
(ja)
|
2017-08-24 |
2020-11-05 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
眼球用医薬組成物
|
|
GB201715194D0
(en)
|
2017-09-20 |
2017-11-01 |
Carrick Therapeutics Ltd |
Compounds and their therapeutic use
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
CA3150681A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
KR102472103B1
(ko)
*
|
2019-12-03 |
2022-11-29 |
삼진제약주식회사 |
국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
|
|
GB201918541D0
(en)
|
2019-12-16 |
2020-01-29 |
Carrick Therapeutics Ltd |
Therapeutic compounds and their use
|
|
UY38994A
(es)
|
2019-12-20 |
2021-07-30 |
Nuevolution As |
Compuestos activos frente a receptores nucleares
|
|
MX2022007265A
(es)
|
2019-12-20 |
2022-09-09 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
WO2021198956A1
(en)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
AU2021245397A1
(en)
|
2020-03-31 |
2022-10-20 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|